Report copyright - Jeffrey Jones, MD, MPH - NCCN Continuing EducationPro_NCCNac16_2up.pdfLog-rank P = .0327 Proportion Achieving OS Phase III RESONATE: Ibrutinib vs Ofatumumab in Previously Treated CLL/SLL
Please pass captcha verification before submit form